ccfDNA/cfDNA Tubes Segment, by Product to Account Larger Share in Blood Collection Tubes for Liquid Biopsy Market during 2023-2031

According to our new research study on "Blood Collection Tubes for Liquid Biopsy Market Forecast to 2031 - Global Analysis - by Product, Application, End User, and Geography," the market was valued at US$ 110.13 million in 2023 and is projected to reach US$ 428.66 million by 2031; it is expected to register a CAGR of 18.5% during 2023-2031. An increase in the prevalence of cancer worldwide and the advantages of liquid biopsy over other diagnostic testing techniques are among the most influential factors responsible for the blood collection tubes for liquid biopsy market growth. However, a lack of skilled professionals hinders the market growth. Technological advancements in liquid biopsy are expected to bring new blood collection tubes for liquid biopsy market trends in the coming years.

Liquid biopsy has revolutionized the way cancer disease states are detected and monitored. Circulating tumor cell (CTC) tubes, intracellular RNA tubes, circulating cell-free DNA (ccfDNA) tubes, cell-free RNA (cfRNA) tubes, genomic DNA (gDNA) tubes, and more advanced blood collecting tubes are available for liquid biopsy. The ccfDNAs, cfRNAs, and extracellular vehicles (EVs, also known as exosomes) are widely used due to which they are gaining considerable attention in cancer diagnosis. Disease-specific exosome or cfRNA analyses require draw-time concentrations of these analytes preserved in collected samples. Major market players focus on introducing new technologically advanced products in the market. For instance, in November 2021, PreAnalytiX GmbH launched QIAsymphony PAXgene Blood ccfDNA Kit (CE-IVD) to fulfill the new EU IVDR requirements. The QIAsymphony PAXgene Blood ccfDNA Kit and the PAXgene Blood ccfDNA Tube (CE-IVD) have been verified as an integrated workflow solution for reproducible and standardized ccfDNA processing in diagnostic laboratories requiring automated solutions.

In November 2023, Illumina, Inc., launched TruSight Oncology 500 ctDNA v2, a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not feasible; the assay is also performed to complement tissue-based testing. In February 2024, Delfi Diagnostics, in collaboration with Immunocore Holdings plc, launched a new cancer monitoring test to examine blood for broken pieces of tumor DNA to explore its use in the detection of multiple malignancies. The DELFI-TF assay delivers a genome-wide measure of the proportion of cfDNA that is derived from a tumor, and it is highly correlated with the mutant allele fraction that is used to evaluate treatment response and resistance to immunotherapies in patients suffering from advanced-stage cancer conditions.

Thus, technological advancements in liquid biopsies for the detection of cancer are expected to introduce new growth trends in the blood collection tubes for liquid biopsy market in the coming years.

Based on product, the blood collection tubes for liquid biopsy market is divided into ccfDNA tubes, cfRNA tubes, CTC tubes, gDNA tubes, intracellular RNA tubes, and others. The ccfDNA/cfDNA tubes segment held the largest market share in 2023. Human venous whole blood is drawn, stored, and transported using ccfDNA tubes. These tubes are also used to stabilize DNA to prepare genomic DNA (gDNA) from the nucleated cellular fraction and circulating cell-free DNA (ccfDNA) from plasma. Whole blood obtained in ccfDNA tubes is used to extract plasma. The ccfDNA kit is then used to process the blood either automatically or manually. Clinical laboratories can use the ccfDNA tubes to stabilize the samples when samples cannot be processed on the same day they are collected. Owing to the unique stabilization chemistry of ccfDNA tubes, collection and processing can take place days apart. Standard EDTA tubes, on the other hand, need to be processed within hours before the cells degenerate and release genomic DNA into the blood plasma, which modifies the original ccfDNA profile.

Additives used in these tubes prevent the degradation of cfDNA, enabling precise analysis in diagnostic procedures such as cancer liquid biopsy and noninvasive prenatal testing (NIPT). They play a critical role in clinical settings where monitoring disease progression or detecting genetic abnormalities requires cfDNA analysis. Moreover, many molecular diagnostic companies are focused on creating new tests for patient screening and monitoring, especially for oncology applications. A safe, clinically acceptable system for blood collection and ccfDNA processing can be used to stabilize a sample for performing ccfDNA extraction after a sample is transported to a different location, which is not achievable with EDTA tubes. The accuracy of molecular diagnostic tests depends on minimizing the possibility of preanalytical errors.

Based on material, the blood collection tubes for liquid biopsy market is divided into glass and plastic.

The global blood collection tubes for liquid biopsy market, based on appplication is segmented into In-Vitro Diagnostics (IVD), and research. In 2023, the in-vitro diagnostics segment is likely to hold a larger share of the market. In vitro diagnostics implies tests carried out in test tubes and similar equipment and not in the body. In vitro testing can be performed in laboratories, hospitals, or at home. The tests can be carried out on a wide range of tools, from simple handheld devices to complicated laboratory equipment, for the accurate diagnosis of patients. The major clinical applications of liquid biopsy include the detection of cancer. The ease of sampling, acceptance among the masses, and cost-effectiveness and reproducibility of outcomes are the prominent benefits of liquid biopsy-based diagnosis. The ongoing clinical studies for the early detection of cancer are resulting in significant strides in liquid biopsy technologies. While circulating tumor DNA (ctDNA) detection solutions are gaining traction, circulating tumor cells (CTC) and extracellular vesicles (EV) technologies are unlocking their potential for liquid biopsy tests. ctDNA solutions are opening new opportunities for use of ctDNA in clinical translation to distinct applications across the cancer. Thus, liquid biopsy is increasingly being employed in in vitro diagnostic procedures with ongoing technological advancements, which, in turn, fuel the demand for blood collection tubes used in the preparatory stages.

Based on end user, the blood collection tubes for liquid biopsy market is divided into genetic diagnostic labs, R&D centers, conventional diagnostic centers, and others.

Biocept Inc, F. Hoffmann-La Roche Ltd; Streck Inc; Norgen Biotek Corp; Exact Sciences Corp; MagBio Genomics, Inc; Zymo Research Corporation; Apostle Sciences; QIAGEN NV; and Greiner Bio-One International GmbH are among the leading companies operating in the global blood collection tubes for liquid biopsy market.

Companies operating in the blood collection tubes for liquid biopsy market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the blood collection tubes for liquid biopsy market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall blood collection tubes for liquid biopsy market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.


Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com